What the FDA labels say about taking them together
Cyclosporine and rosuvastatin
Rosuvastatin's FDA label of September 4, 2026 names cyclosporine in its drug interactions section; cyclosporine's label does not name rosuvastatin itself but warns about its class (Statins). The rosuvastatin label: “Mechanism and Clinical Effect (s): Cyclosporine increased rosuvastatin exposure 7-fold.”
Check it at the source: the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation); the rosuvastatin FDA label on DailyMed (effective September 4, 2026, ScieGen Pharmaceuticals, Inc.).
What does the cyclosporine label say about rosuvastatin?
Cyclosporine's label does not name rosuvastatin itself; it warns about its class (Statins):
Cyclosporine label, drug interactionsCyclosporine may reduce the clearance of digoxin, colchicine, prednisolone, HMG-CoA reductase inhibitors (statins), aliskiren, bosentan, dabigatran, repaglinide, NSAIDs, sirolimus, etoposide, and other drugs.
Cyclosporine label, drug interactionsHMG-CoA Reductase Inhibitors (Statins) Literature and postmarketing cases of myotoxicity, including muscle pain and weakness, myositis, and rhabdomyolysis, have been reported with concomitant administration of cyclosporine with lovastatin, simvastatin, atorvastatin, pravastatin, and rarely fluvastatin.
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
What does the rosuvastatin label say about cyclosporine?
Rosuvastatin label, drug interactionsMechanism and Clinical Effect (s): Cyclosporine increased rosuvastatin exposure 7-fold.
Rosuvastatin label, warnings and precautionsSteps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis The concomitant use of rosuvastatin with cyclosporine or gemfibrozil is not recommended.
Source: FDA drug label (Crestor, NDA021366), AstraZeneca Pharmaceuticals LP, effective April 29, 2026 (SPL set 325a5d0e-9a72-4015-9fcd-1655fb504cee), via openFDA
Source: FDA drug label (Rosuvastatin), ScieGen Pharmaceuticals, Inc., effective September 4, 2026 (SPL set ee4933c5-0d97-494d-ac0f-2083e0100836), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclosporine | Rosuvastatin | |
|---|---|---|
| Labeled for | Organ transplant rejection, Rheumatoid arthritis | Heart attack and coronary artery disease, High cholesterol, High triglycerides, Stroke prevention |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $1.04 per unit 0.05% eye emulsion | $0.0692 per tablet 40 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once